Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 2200 participants.
Also called NCT02642419
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 2,200 participants
- Sponsor
- Japan Cardiovascular Research Foundation
- Registry
-
NCT02642419
-
- Other papers using this trial's data
- Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease
- Aspirin versus P2Y12 inhibitors with anticoagulation therapy for atrial fibrillation
- Risk prediction score for clinical outcome in atrial fibrillation and stable coronary artery disease
- Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE Trial
- Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysis
- The impact of kidney function in patients on antithrombotic therapy: a post hoc subgroup analysis focusing on recurrent bleeding events from the AFIRE trial
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Japan
- Registry status
- Unknown status
Technical summary
Registry record NCT02642419. Randomized; no masking; primary purpose treatment. Start 2015-01 (registry gives no type); primary completion 2017-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study
- Acronym
- AFIRE
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel)
- Intervention (Drug)
- Rivaroxaban
- Lead sponsor
- Japan Cardiovascular Research Foundation
Record details
- Record id
cardio:ct-nct02642419- Content hash
3acaa618119bdacbe4db13b95a2ce3d9d33a959ab4650ecb0478df61c31ecb70